Deep venous thrombosis risk assessment, incidence, and prophylaxis in foot and ankle surgery

Clinics in Podiatric Medicine and Surgery

Volumn 20, Issue 2, 2003, Pages 269-289

  Slaybaugh, Randall S ^a,b   Beasley, Bradley D ^a   Massa, Eric G ^a,c  

^a GRANT MEDICAL CENTER   (United States)

^b General Medical Consultants   (United States)

^c Total Foot and Ankle of Ohio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DALTEPARIN; ENOXAPARIN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN; TINZAPARIN; WARFARIN;

ADULT; ALGORITHM; ANKLE; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; CATHETER; CIGARETTE SMOKING; COLOR ULTRASOUND FLOWMETRY; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; DRUG INDUCED DISEASE; FEMALE; FOOT SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; IMMOBILIZATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBESITY; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL PATIENT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING; VEIN THROMBOSIS; VENA CAVA FILTER;

EID: 0037618877     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-8422(03)00007-7     Document Type: Review

References (53)

1. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism for healthcare professionals. The Council on Thrombosis, American Heart Association. Circulation 1996;93:2212-45.
2. Cirlincione AS, Mendicinio R, Catanzariti AR, et al. Low-molecular-weight heparin for deep vein thrombosis prophylaxis in foot and ankle surgery: a review. J Foot Ankle Surg 2001;40(2):96-100.
3. Mizel MS, Temple HT, Michelson JD, et al. Thromboembolism after foot and ankle surgery. Clin Orthop 1998;348:180-5.
4. Solis G, Saxby T. Incidence of DVT following surgery of the foot and ankle. Foot Ankle 2002;23(5):411-4.
5. Mantilla CB, Horlocker TT, Schroeder DR, et al. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology 2002;96(5):1140-6.
6. Virchow R. Neuer fall von todlicher. Embolie der lungenarterien. Arch Pathol Anat 1856;10:225.
7. Servatjoo P. Deep venous thrombosis: the dilemma of diagnosis. Journal of the American Podiatric Medical Association 1997;87(5):224-32.
8. Gschwandtner ME, Ehringer H. Microcirculation in chronic venous insufficiency. Vasc Med 2001;6(3):169-79.
9. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90(3):1004-8.
10. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001;113(3):630-5.
11. Gerhardt A, Sharft RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342(6):374-80.
12. Greaves M, Cohen H, MacHin ST, et al. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109(4):704-15.
13. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997;127(10):895-903.
14. Rand JH, Wu XX, Andree HA, et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997;337(3):154-60.
15. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346(8983):1133-4.
16. Federman DG, Kirsner RS. An update on hypercoagulable disorders. Arch Intern Med 2001;161(8):1051-6.
17. Martinelli I, Bucciarelli P, Margaglione M, et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000;111(4):1223-9.
18. Winkler UH. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 2000;62(Suppl 2):11S-20S.
19. Harris WH, Salzman EW, Athanasoulis C, et al. Comparison of warfarin, low-molecular weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg 1974;56A(8):1552-62.
20. Kennedy D, Setnik G, Li J. Physical examination findings in deep venous thrombosis. Emerg Med Clin N Am 2001;19(4):869-76.
21. Rolfe MW, Solomon DA. Lower extremity venography. Chest 1999;116:853-64.
22. Elliott CG. The diagnostic approach to deep venous thrombosis. Semin Respir Crit Care Med 2000;21(6):511-9.
23. Freyburger G, Trillaud H, Labrouche S, et al. D-dimer strategy in thrombosis exclusion. Thromb Haemost 1998;70:32-7.
24. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336(21):1506-11.
25. Owings JT, Gosselin RC, Battistella FD, et al. Whole blood d-dimer assay: an effective noninvasive method to rule out pulmonary embolism. J Trauma 2000;48(5):795-800.
26. Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and d-dimer testing. Ann Int Med 2001;135(2):108-11.
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994;308(22):235-46.
28. Grace DL, Bourne RB. Prophylactic low-dose aspirin therapy in patients having hip fracture surgery or elective arthroplasty. J Bone Joint Surg 2001;83A(8):a1277.
29. Guyatt G, Schunemann H, Cook D, et al. Grades of recommendation for antithrombotic agents. Chest 2001;119(1):3S-7S.
30. Haas SB, Insall JN, Scuderi GR, et al. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg 1990;72A(1):27-31.
31. Harris WH, Athanasoulis CA, Waltman AC, et al. High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement. J Bone Joint Surg 1982;64A(1):63-6.
32. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1):8S-21S.
33. Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Rel Res 1996;324:251-8.
34. McCardel BR, Lachiewicz PF, Jones K. Aspirin prophylaxis and surveillance of pulmonary embolism and deep vein thrombosis in total hip arthroplasty. J Arthroplasty 1990;5(2):181-5.
35. McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin and intermittent calf and thigh compression. BMJ 1980;23:514-7.
36. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997;126(7):528-31.
37. Stulberg BN, Dorr LD, Ranawat CS, et al. Aspirin prophylaxis for pulmonary embolism following total hip arthroplasty. Clin Orthop Rel Res 1982;168:119-23.
38. Sarmiento A, Goswami ADK. Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. J Bone Joint Surg 1999;81A(3):339-46.
39. Guyton DP, Khayat A, Schereiber H. Pneumatic compression stockings and prostaglandin synthesis: a pathway of fibrinolysis? Crit Care Med 1985;13:266.
40. Hirsh J, Dalen JE, Guyatt G. The sixth (2000) ACGP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. Chest 2001;119(1):1S-2S.
41. Organon Sanofi-Synthelabo LLC. Arixtra® prescribing information. Available at: http://www.pharmacist.com/new_drug/arixtra.cfm. Accessed Jan 1-4, 2002.
42. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993;119(9):874-81.
43. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1):64S-94S.
44. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(1):176S-93S.
45. Levy JH. Novel intravenous antithrombins. Am Heart J 2001;141(6):1043.
46. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23:197-202.
47. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340(12):901-7.
48. Lensing AW, Prandoni P, Prins MH, et al. Deep-vein thrombosis. Lancet 1999;353(9151):479-85.
49. Ponchon M, Goffette P, Hainaut P. Temporary vena caval filtration. Preliminary clinical experience with removable vena caval filters. Acta Clin Belg 1999;54(4):223-8.
50. Howard RJ. Surgical infections. In: Schwartz SI, Shires GT, Spencer FC, et al, editors. Principles of surgery. 7th edition. New York: McGraw-Hill; 1999. p. 131.
51. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001;38(Suppl 5):12-9.
52. Simon MA, Mass DP, Zarins CK, et al. The effect of a thigh tourniquet on the incidence of deep vein thrombosis after operations on the fore part of the foot. J Bone Joint Surg 1982;64A(2):188-91.
53. Talbott EO, Zborowski JV, Sutton-Tyrrell K, et al. Cardiovascular risk in women with polysystic ovary syndrome. Obstet Gynecol Clin N Am 2001;28(1):113-33.